Orbis Medicines

Orbis Medicines is a biotech company in Copenhagen, Denmark, founded in 2024. It has raised $93.0M across 1 round, most recently a $93.0M Series B in January 2025.

A new era for oral macrocycle drug discovery

Headquarters
Copenhagen
Employees
11–50
Founded
2024
Business Model
B2B
Total Funding
$93.0M
Last Round
$93.0M Series BJan 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round for this company. The full record is or through the API.

About

Orbis Medicines is pioneering a new era for oral macrocycle drug discovery using its nGen platform, which systematically designs and tests macrocyclic compounds called nCycles optimized for oral bioavailability and membrane permeability. The company's pipeline targets diseases historically treated with injectable biologics, aiming to provide accessible oral alternatives. Orbis combines high-throughput synthesis, proprietary DNA-encoded libraries of nearly 100 billion compounds, and deep learning to accelerate macrocycle medicine.

Summary

It lists 11–50 employees. It has raised $93.0M in total across 1 round, most recently a $93.0M Series B round in Jan 2025.

Tech & App Stack

2 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Data from Indexed.vcUpdated
Series BSeries BJan 2025
$93.0M

Similar Companies

Abogen Biosciences

Abogen Biosciences develops RNA therapeutics using integrated mRNA design, lipid nanoparticle del...

Suzhou, China201–500Biotech, Drug Discovery
Extension RoundTotal funding$1.2BNov 2021
Mirador Therapeutics

Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...

San Diego, United States11–50Biotech, Drug Discovery
Series BTotal funding$650.0MOct 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech, Healthcare
Private EquityTotal funding$647.0MFeb 2026
Neumora TherapeuticsIPO

Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...

Watertown, United States51–200Biotech, Drug Discovery
Series BTotal funding$612.0MOct 2022
AsymchemIPO

Asymchem is a pharmaceutical CDMO providing R&D, chemistry, manufacturing, and control services t...

Tianjin, China5001–10000Biotech, Drug Discovery
Private EquityTotal funding$2.3BFeb 2020
Paratek PharmaceuticalsAcquired

Paratek Pharmaceuticals develops and delivers innovative treatments for serious infectious diseas...

Boston, United States201–500Biotech, Healthcare
ConvertibleTotal funding$1.8BApr 2018

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Orbis Medicines on Indexed.vc
<a href="https://indexed.vc/companies/orbis-medicines"><img src="https://indexed.vc/api/badge/company/orbis-medicines" alt="Orbis Medicines on Indexed.vc" width="260" height="76" /></a>